Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02286947 · ClinicalTrials.gov registry record · Phase 2
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
A Phase 2 study, sponsored by Sarepta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02286947 is a Phase 2 study that has completed, run by Sarepta Therapeutics. The registered enrollment target is 24 participants.
The verdict
NCT02286947, a Phase 2 study, has completed, sponsored by Sarepta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
Interventions
- DRUG Eteplirsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2014-11 |
| Est. Completion | 2018-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02286947
The ClinicalTrials.gov registry entry for NCT02286947 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eteplirsen is the first listed.
NCT02286947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02286947 about?
NCT02286947 is a clinical study titled "Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy". The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
What is the current status of trial NCT02286947?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2014-11. Estimated completion is 2018-03-23.
What interventions are being tested in trial NCT02286947?
The interventions under investigation include: Eteplirsen (DRUG).
Who is sponsoring clinical trial NCT02286947?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.